Indian Pharmaceutical companies, from Sun Pharma Ltd., to Lupin Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Gland Pharma Ltd., will be reacting on Wednesday, April 9, after US President Donald Trump said that he will be announcing major tariffs on the Pharma sector soon. Speaking at the Republican NRCC event, Trump said that major […]
Pharma Stocks Crash: Donald Trump says tariffs will be at ‘never seen before’ levels – CNBC TV18
Shares of Indian Pharma Companies, Aurobindo Pharma, IPCA Laboratories, Lupin and others fell up to 5% on Friday, April 4, after US President Donald Trump remarked about the upcoming tariffs on the sector. “Pharma tariffs are going to come in at levels you have never seen before. We are looking at pharmaceuticals as a separate […]
Trump Reciprocal Tariffs: These Indian Pharma companies are likely to be impacted – CNBC TV18
April 2 is the day that Donald Trump’s proposed reciprocal tariffs kick in, even as the world awaits an official announcement on the scope and quantum of tariffs from the US President. A sector in the line of fire is Pharma, as majority of Indian Pharma exports head to the US. However, the White House […]
Lupin gets tentative USFDA approval for Amifampridine tablets – CNBC TV18
Global pharmaceutical giant Lupin Ltd. on Monday announced a significant milestone in its expansion strategy within the US market, securing tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amifampridine Tablets, 10 mg. This approval positions Lupin to tap into a substantial market opportunity for […]
Lupin launches generic heart drug rivaroxaban in US – CNBC TV18
Drug firm Lupin Ltd on Friday (March 7) said it has launched rivaroxaban tablets USP, 2.5 mg, in the US market following final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA). “Lupin today announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval […]
Lupin shares surge after Citi upgrades betting on strong US sales potential – CNBC TV18
Brokerage firm Citi on Wednesday, March 5, upgraded its rating on Lupin Ltd. and revised its price target higher by 19%. The brokerage upgraded the stock to “buy” from its earlier rating of “sell” and increased its price target to ₹2,260 from its previous target of ₹1,900. This indicates a 15.7% upside potential for Lupin’s […]
Trade Setup for February 24: Nifty bulls’ resolve to defend 22,800 to be tested further post US crash – CNBC TV18
By the close of Friday’s trade, the bulls would have patted themselves on the back for relentlessly defending the 22,750 – 22,800 zone on the Nifty for at least the last eight trading sessions. That resolve and determination is likely to be put through a gruelling test on Monday, particularly after the sell-off that was […]
Tech analysts see upside in UPL, Bajaj Finance, Cholamandalam Finance, GAIL, SBI Cards and Lupin – CNBC TV18
SUMMARY On Friday, market tech analysts Sudeep Shah, Mitessh Thakkar and Shrikant Chouhan recommended these stocks for the short term. 1 / 12 Technical analysts Sudeep Shah of SBI Securities, Mitessh Thakkar of earningwaves.com and Shrikant Chouhan of Kotak Securities share these top stock picks for the day. 2 / 12 Buy for a target […]
Lupin shares in focus after Q3 profit increases nearly 40% – CNBC TV18
Lupin shares are in focus after the company reported its third quarter earnings on Wednesday, February 12. Company Value Change %Change The company reported a profit after tax of ₹8,589 crore, a 38.8% increase from the previous year’s ₹6,187 crore. Its total revenue from operations was up 102.7% at ₹57,677 crore from last fiscal’s ₹51,974 […]
Stocks to Watch on February 11: Eicher Motors, Escorts Kubota, Sona BLW, Shriram Properties and more – CNBC TV18
1 / 9 Eicher Motors | The company posted a 17.5% increase in net profit to ₹1,170.5 crore in the third quarter of FY25, up from ₹996 crore a year ago. However, the figure came in lower than the CNBC-TV18 poll estimate of ₹1,191 crore. The company’s revenue rose 19% on-year to ₹4,973 crore, compared […]